ESCRS Binkhorst lecture 2002: Pseudophakic preservative maculopathy.
Miyake Kensaku, Ibaraki Nobuhiro, Goto Yoko, Oogiya Shin, Ishigaki Junko, Ota Ichiro, Miyake Sampei
AI Summary
Glaucoma eyedrops, especially with preservatives, can cause pseudophakic cystoid macular edema by increasing inflammation. This highlights the need for preservative-free options to prevent maculopathy.
Abstract
Many antiglaucoma eyedrops are reported to cause cystoid macular edema (CME) in aphakia and pseudophakia. We review 4 clinical and laboratory studies that compare the incidence of CME in early postoperative pseudophakia in eyes that received preserved latanoprost and timolol, nonpreserved timolol, and the preserved and nonpreserved vehicle for these drugs and looked at the morphological damage to cells and the changes in the indicators of cytokine and prostaglandin (PG) synthesis caused by latanoprost and timolol and the preservative benzalkonium chloride. Based on the findings of these studies, which indicate that the preservative causes increased synthesis of PGs and other substances and intensified postoperative inflammation, the term pseudophakic preservative maculopathy is proposed for CME caused by antiglaucoma eyedrops.
MeSH Terms
Shields Classification
Related Articles5
Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: a review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys.
ReviewLatanoprost and clinically significant cystoid macular edema after uneventful phacoemulsification with intraocular lens implantation.
Retrospective StudyLatanoprost and cystoid macular edema in high-risk aphakic or pseudophakic eyes.
Case SeriesVogt-Koyanagi-Harada-like disease secondary to anticancer treatment: a multicentre case series.
Case SeriesUNITED KINGDOM DATABASE STUDY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX) FOR MACULAR EDEMA RELATED TO RETINAL VEIN OCCLUSION.
Observational StudyIs this article assigned to the wrong chapter(s)? Let us know.